Allergan, the pharmaceutical giant, is purchasing tiny Tobria Therapeutics in an interesting acquisition.
The deal is initially for $28.35 per share in cash, however according to the statement from Allergan, the deal could balloon to much more.
Tobria, which closed trading on Monday at $4.74 a share and a market cap of just $89 million, is developing two drugs to treat NASH disease. According to the Allergan statement, NASH is a build up of fat in the liver for unknown reasons that can eventually lead to liver failure.
Tobria has two drugs under development that used together could help to treat read more >>>